ARTICLE | Deals
Deal for up to $1.1B with ‘significant upfront payment’ rewards syndicate including Westlake and Versant, gives pharma three preclinical programs for muscular dystrophies
By Paul Bonanos, Director of Biopharma Intelligence
November 21, 2024 8:40 PM UTC
Updated on Nov 21, 2024 at 11:11 PM UTC
In keeping with CEO Vas Narasimhan’s preference to restrict Novartis’ M&A deals to buyouts for less than $5 billion, the pharma has added three preclinical gene therapies for neuromuscular disorders via its takeout of privately held Kate Therapeutics.
Novartis AG (SIX:NOVN; NYSE:NVS) didn’t disclose the upfront price for Kate Therapeutics Inc., but said the deal’s total value could escalate to $1.1 billion including contingent milestones. The deal includes an upfront payment “significantly greater than Kate’s $51 million series A round last year,” according to a source familiar with the deal...
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654283/still-seeking-smaller-bolt-ons-novartis-takes-out-gene-therapy-play-kate